US FDA accepts aripiprazole refiling
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review Lundbeck and Otsuka Pharmaceutical's resubmission for Abilify (depot formulation aripiprazole) as a potential treatment for schizophrenia, setting a new PDUFA action date of 28 February 2013.